Well differentiated arginase-1 negative hepatocellular carcinoma

Obiorah, Ifeyinwa E.; Chahine, Joeffrey J.; Park, Byoung Uk; Ko, Kyungmin; deGuzman, Jose; Kallakury, Bhaskar

doi:10.21037/tgh.2019.08.01

Cited by 9 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Targeted therapy for cancer has also been widely studied recently. The targeted therapy drugs, such as sorafenib and sunitinib, have good clinical effects ( 25 ). The present study found notably high expression of ANLN in human HCC tissues.…”

Section: Discussionmentioning

confidence: 99%

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common type of tumor with high mortality worldwide. Investigations associated with the molecular etiology of HCC and screening novel therapeutic targets are still urgently in need. Anillin (ANLN), as a type of evolutionarily conserved actin-binding protein, is involved in multiple cellular processes. ANLN widely affected the progression and metastasis of several types of cancer, and its overexpression was frequently demonstrated in previous studies. The present study demonstrated high expression of ANLN in human HCC tissues, which was also associated the prognosis of patients with HCC. The associations between ANLN expression and the clinicopathological features were determined, including the number of tumor nodes (P=0.011) and tumor size (P=0.003) of patients with HCC. It was found that ANLN promoted cell proliferation, invasion and migration of HCC cells in vitro , and affected tumor growth in vivo . Therefore, ANLN is suggested as a promising therapeutic target for the treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Because arginase-1 expression is usually retained in hepatocellular carcinoma, a cancer derived from hepatocytes, the immunohistochemical detection of arginase expression is commonly used to support the difficult distinction of hepatocellular carcinoma from cholangiocellular carcinoma and metastases to the liver [ 5 ]. This procedure is supported by more than 20 studies demonstrating arginase-1 expression in 80–100% of hepatocellular carcinomas [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ].…”

Section: Introductionmentioning

confidence: 77%

“…Multiple studies have suggested that arginase-1 expression of tumor cells is largely absent in other important tumor types, such as renal cell carcinomas [ 8 , 25 ], ductal adenocarcinoma of the pancreas [ 8 , 21 ], gastric adenocarcinoma [ 25 ], esophageal adenocarcinoma [ 25 ], adenocarcinoma of the lung [ 25 ], and in lobular breast cancer [ 25 ]. The extent to which arginase-1 expression is specific for hepatocellular carcinoma is still unclear, however.…”

Section: Introductionmentioning

confidence: 99%

Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Arginase-1 catalyzes the conversion of arginine to ornithine and urea. Because of its predominant expression in hepatocytes, it serves as a marker for hepatocellular carcinoma, although other tumor entities can also express arginase-1. To comprehensively determine arginase-1 expression in normal and neoplastic tissues, tissue microarrays containing 14,912 samples from 117 different tumor types and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. In normal tissues, arginase-1 was expressed in the liver, the granular layer of the epidermis, and in granulocytes. Among tumors, a nuclear and cytoplasmic arginase-1 immunostaining was predominantly observed in hepatocellular carcinoma, where 96% of 49 cancers were at least moderately positive. Although 22 additional tumor categories showed occasional arginase immunostaining, strong staining was exceedingly rare in these entities. Staining of a few tumor cells was observed in squamous cell carcinomas of various sites. Staining typically involved maturing cells with the beginning of keratinization in these tumors and was significantly associated with a low grade in 635 squamous cell carcinomas of various sites (p = 0.003). Teratoma, urothelial carcinoma and pleomorphic adenomas sometimes also showed arginase expression in areas with squamous differentiation. In summary, arginase-1 immunohistochemistry is highly sensitive and specific for hepatocellular carcinoma if weak and focal staining is disregarded.

show abstract

“…Briefly, samples were collected, fixed by formalin and embedded by paraffin. Immunostaining was performed using the immune peroxidase method, referring to Obiorah et al (2019). Pretreated 4-µm-thick sections from the tissue blocks were incubated with monoclonal Glypican-3 (GPC-3) antibody and monoclonal Arginase-1 (ARG-1) antibody, purchased from Maxim (Fuzhou, China), respectively.…”

Section: The Data Of Rna-seqmentioning

confidence: 99%

RNA binding proteins involved in regulation of protein synthesis to initiate biogenesis of secondary tumor in hepatocellular carcinoma in mice

Tang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background The tumor microenvironment (TM) in close contact with cancer cells is highly related to tumor growth and cancer metastasis. This study is to explore the biogenesis mechanism of a secondary hepatocellular carcinoma (HCC) based on the function of RNA binding proteins (RBPs)-encoding genes in the physiological microenvironment (PM). Methods The healthy and HCC mice were used to isolate the PM, pre-tumor microenvironment (PTM), and TM. The samples were analyzed using the technology of RNA-seq and bioinformatics. The differentially expressed RBPs-encoding genes (DERs) and differentially expressed DERs-associated genes (DEDs) were screened to undergo GO and KEGG analysis. Results 18 DERs and DEDs were identified in the PTM vs. PM, 87 in the TM vs. PTM, and 87 in the TM vs. PM. Those DERs and DEDs participated in the regulation of gene expression at the levels of chromatin conformation, gene activation and silencing, splicing and degradation of mRNA, biogenesis of piRNA and miRNA, ribosome assemble, and translation of proteins. Conclusion The genes encoding RBPs and the relevant genes are involved in the transformation from PM to PTM, then constructing the TM by regulating protein synthesis. This regulation included whole process of biological genetic information transmission from chromatin conformation to gene activation and silencing to mRNA splicing to ribosome assemble to translation of proteins and degradation of mRNA. The abnormality of those functions in the organic microenvironments promoted the metastasis of HCC and initiated the biogenesis of a secondary HCC in a PM when the PM encountered the invasion of cancer cells.

show abstract

Well differentiated arginase-1 negative hepatocellular carcinoma

Cited by 9 publications

References 23 publications

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma

RNA binding proteins involved in regulation of protein synthesis to initiate biogenesis of secondary tumor in hepatocellular carcinoma in mice

Contact Info

Product

Resources

About